Key result
Dabigatran triggers biopsy-proven anticoagulant-related nephropathy causing severe acute kidney injury requiring hemodialysis.
Why the study?
Dabigatran related nephropathy had previously only been reported in patients with concurrent or undiagnosed IgA nephropathy.
Case Report (n=1)
No
This case demonstrates that dabigatran can induce biopsy-proven anticoagulant-related nephropathy leading to dialysis-dependent acute kidney injury even in patients without underlying IgA nephropathy.
Answers are grounded in this paper and cite their sources.
Dabigatran may cause dialysis-requiring nephropathy without IgA; extends the condition's reported spectrum and leaves risk stratification open.
We describe a case of biopsy-proven dabigatran related nephropathy in a patient without underlying IgA nephropathy. To date, dabigatran related nephropathy was only reported in patients with concurrent or undiagnosed IgA nephropathy, suggesting that it may predispose patients to dabigatran associated injury. The patient is an 81-year-old woman with multiple medical comorbidities, including nonvalvular atrial fibrillation, who was anticoagulated with dabigatran. She presented to hospital with acute kidney injury in the setting of volume overload. Her estimated glomerular filtration rate decreased from a baseline of 57 mL/min/1.73 m 2 to 4 mL/min/1.73 m 2 , necessitating hemodialysis. Renal ultrasound findings, fractional excretion of sodium, and urinalysis suggested acute kidney injury. Renal biopsy showed acute tubular injury, tubular red blood cell casts, and an absence of active glomerulonephritis, similar to the pathological findings of warfarin related nephropathy. A diagnosis of anticoagulant related nephropathy secondary to dabigatran was therefore established. This case demonstrates that dabigatran, like warfarin, may increase tubular bleeding risk in patients, irrespective of underlying kidney or glomerular disease.
No takes yet. Share an insight, caveat, or question.
Sharfuddin et al. (2018) conducted a case report in Anticoagulant-related nephropathy secondary to dabigatran in nonvalvular atrial fibrillation (n=1). Dabigatran was evaluated on Biopsy-proven anticoagulant-related nephropathy and severe acute kidney injury requiring hemodialysis. Dabigatran induced biopsy-proven anticoagulant-related nephropathy without underlying IgA nephropathy, decreasing eGFR from 57 to 4 mL/min/1.73 m2 and necessitating hemodialysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: